Literature DB >> 23977544

Multimodality therapy for malignant pleural mesothelioma.

Walter Weder1, Isabelle Opitz.   

Abstract

Entities:  

Year:  2012        PMID： 23977544      PMCID： PMC3741801          DOI： 10.3978/j.issn.2225-319X.2012.11.12

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN： 2225-319X


× No keyword cloud information.
  42 in total

1.  The MARS feasibility trial: conclusions not supported by data.

Authors:  Walter Weder; Rolf A Stahel; Paul Baas; Urania Dafni; Marc de Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; David J Sugarbaker; Nico van Zandwijk
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

2.  Intraoperative photodynamic therapy for malignant mesothelioma.

Authors:  H I Pass; Z Tochner; T DeLaney; P Smith; W Friauf; E Glatstein; W Travis
Journal:  Ann Thorac Surg       Date:  1990-10       Impact factor: 4.330

Review 3.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

4.  Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.

Authors:  Ritu R Gill; William G Richards; Beow Y Yeap; Shin Matsuoka; Andrea S Wolf; Victor H Gerbaudo; Raphael Bueno; David J Sugarbaker; Hiroto Hatabu
Journal:  AJR Am J Roentgenol       Date:  2012-02       Impact factor: 3.959

5.  Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.

Authors:  Joseph S Friedberg; Melissa J Culligan; Rosemarie Mick; James Stevenson; Stephen M Hahn; Daniel Sterman; Salman Punekar; Eli Glatstein; Keith Cengel
Journal:  Ann Thorac Surg       Date:  2012-05       Impact factor: 4.330

6.  Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.

Authors:  Terry T Lee; Darcie L Everett; Hui-Kuo G Shu; Thierry M Jahan; Mack Roach; Joycelyn L Speight; Robert B Cameron; Theodore L Phillips; Albert Chan; David M Jablons
Journal:  J Thorac Cardiovasc Surg       Date:  2002-12       Impact factor: 5.209

7.  Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience.

Authors:  J D Lee; S Perez; H J Wang; R A Figlin; E C Holmes
Journal:  J Surg Oncol       Date:  1995-12       Impact factor: 3.454

8.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

9.  Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies.

Authors:  O Monneuse; A C Beaujard; B Guibert; F N Gilly; P Mulsant; P Y Carry; M Benoit; O Glehen
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma.

Authors:  M Colleoni; F Sartori; F Calabro; P Nelli; G Vicario; G Sgarbossa; F Gaion; L Bortolotti; L Toniolo; P Manente
Journal:  Tumori       Date:  1996 Jan-Feb
View more
  10 in total

Review 1.  Radical multimodality therapy for malignant pleural mesothelioma.

Authors:  Omar Abdel-Rahman; Zeinab Elsayed; Hadeer Mohamed; Mostafa Eltobgy
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

2.  Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.

Authors:  R Berardi; M Caramanti; I Fiordoliva; F Morgese; A Savini; S Rinaldi; M Torniai; M Tiberi; C Ferrini; M Castagnani; F Rovinelli; A Onofri; S Cascinu
Journal:  Support Care Cancer       Date:  2014-08-21       Impact factor: 3.603

3.  Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.

Authors:  Mayura Meerang; Karima Bérard; Martina Friess; Byron K Y Bitanihirwe; Alex Soltermann; Bart Vrugt; Emanuela Felley-Bosco; Raphael Bueno; William G Richards; Burkhardt Seifert; Rolf Stahel; Walter Weder; Isabelle Opitz
Journal:  Mol Oncol       Date:  2016-06-25       Impact factor: 6.603

Review 4.  Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.

Authors:  Isabelle Opitz; Raphael Bueno; Eric Lim; Harvey Pass; Ugo Pastorino; Mattia Boeri; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2014-03-12       Impact factor: 4.191

5.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 6.  Multimodality treatment of malignant pleural mesothelioma.

Authors:  Lawek Berzenji; Paul Van Schil
Journal:  F1000Res       Date:  2018-10-22

7.  Chemo-manipulation of tumor blood vessels by a metal-based anticancer complex enhances antitumor therapy.

Authors:  Tina Riedel; Sabrina Cavin; Hubert van den Bergh; Thorsten Krueger; Lucas Liaudet; Hans-Beat Ris; Paul J Dyson; Jean Y Perentes
Journal:  Sci Rep       Date:  2018-07-06       Impact factor: 4.379

8.  Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.

Authors:  Christina Schröder; Isabelle Opitz; Matthias Guckenberger; Rolf Stahel; Walter Weder; Robert Förster; Nicolaus Andratschke; Olivia Lauk
Journal:  Front Oncol       Date:  2019-09-26       Impact factor: 6.244

9.  The prognostic value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography parameters in patients with malignant pleural mesothelioma.

Authors:  Bülent Mustafa Yenigün; Yusuf Kahya; Çiğdem Soydal; Nihal Ata Tutkun; Gökhan Kocaman; Emre Muhammed Koçak; Elgin Özkan; Serpil Dizbay Sak; Ayten Kayı Cangır
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-01-13       Impact factor: 0.332

Review 10.  Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies.

Authors:  Sotiris Papaspyros; Sayonara Papaspyros
Journal:  ISRN Surg       Date:  2014-02-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.